Private Insurers Deny Over Half of All Claims for Hepatitis C Drugs

Both private and public insurers in the US are still denying patients accessing to cutting edge therapies for hepatitis C at alarmingly high rates, according to research published in the journal Open Forum Infectious Diseases. The study – conducted by researchers at the Perelman School of Medicine at the University of Pennsylvania – found that over 52 percent of patients with private insurance have been denied coverage, while more than 34 percent of Medicaid patients and nearly 15 percent of patients with Medicare coverage have faced the same barriers to treatment.